Wassilios G. Meissner
Expertise in
15
conditions

Wassilios G. Meissner

Bordeaux, FR 
Expertise in
15
conditions
Bordeaux, FR 

Overview

Wassilios Meissner practices practicing medicine in Bordeaux, France.

Meissner is highly rated in 15 conditions, according to our data. Their clinical expertise encompasses Multiple System Atrophy, Familial Dysautonomia, Movement Disorders, Parkinson's Disease, and Deep Brain Stimulation.

They are actively involved in clinical research, co-authoring 237 peer reviewed articles and participating in 7 clinical trials.

Locations

Bordeaux, France
Other Locations
Equipe 01-Neuropsychologie Interventionnelle L'Institut Mondor De Recherches Biomédicales, Université Paris Est Créteil, UMR 1239, CIC 1413, CIC 1402, CNRS UMR 7104, CIC 1414, CHU De Caen, Caen, France
Laloeuf, France
2, Avenue Martin Luther King, Limoges, 87025, France
France
Pessac-sur-dordogne, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Morphological and Functional Investigation of the Serotoninergic System in Multiple System Atrophy: a 18F-MPPF PET Study
Morphological and Functional Investigation of the Serotoninergic System in Multiple System Atrophy: a 18F-MPPF PET Study
Enrollment Status: Completed
Publish Date: June 09, 2026
Intervention Type: Other, Drug, Radiation
Study Phase: Not Applicable
Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone
Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone
Enrollment Status: Completed
Publish Date: February 05, 2026
Intervention Type: Drug
Study Drug: Deferiprone
Study Phase: Phase 2
French Validation Study of a New Scale for Neuropsychiatric Fluctuations in Parkinson Disease
French Validation Study of a New Scale for Neuropsychiatric Fluctuations in Parkinson Disease
Enrollment Status: Completed
Publish Date: December 22, 2025
Intervention Type: Other
Study Phase: Not Applicable
A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients With Parkinson's Disease
A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients With Parkinson's Disease
Enrollment Status: Completed
Publish Date: April 10, 2024
Intervention Type: Drug
Study Phase: Phase 2
Care for Late Stage Parkinsonism
Care for Late Stage Parkinsonism
Enrollment Status: Completed
Publish Date: April 28, 2021
Intervention Type: Other
Study Phase: Not Applicable
Oligomeric Alpha-synuclein Levels as a Biomarker for Multiple System Atrophy
Oligomeric Alpha-synuclein Levels as a Biomarker for Multiple System Atrophy
Enrollment Status: Completed
Publish Date: June 27, 2019
Double-Blind Randomized Placebo-Controlled Cross-Over Phase IIa Trial to Evaluate Efficacy of CVXL-0107 on Parkinson-Related Symptoms and Levodopa-Induced Dyskinesia in Advanced Parkinson's Disease Patients Using a Levodopa Challenge Test
Double-Blind Randomized Placebo-Controlled Cross-Over Phase IIa Trial to Evaluate Efficacy of CVXL-0107 on Parkinson-Related Symptoms and Levodopa-Induced Dyskinesia in Advanced Parkinson's Disease Patients Using a Levodopa Challenge Test
Enrollment Status: Completed
Publish Date: July 24, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

236 Total Publications

Distinct neurostructural, cognitive, and neuropsychiatric associations of plasma p-tau217, and Aβ42/40 in Parkinson's disease and aging cohorts.
Distinct neurostructural, cognitive, and neuropsychiatric associations of plasma p-tau217, and Aβ42/40 in Parkinson's disease and aging cohorts.
Journal: Frontiers in aging neuroscience
Published: April 13, 2026

Frequently Asked Questions about Wassilios G. Meissner

Is Wassilios G. Meissner a top-rated expert for Multiple System Atrophy?

MediFind is an objective health platform that identifies experts based on real-world data. Wassilios G. Meissner is classified as an Elite expert for Multiple System Atrophy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Wassilios G. Meissner participate in research or clinical trials?

Yes. Wassilios G. Meissner has published 236 articles and abstracts on conditions like Multiple System Atrophy. You can view a list of Wassilios G. Meissner's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Meissner's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 26 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile